CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets
D516AC00001
Phase 3 small_molecule active
Quick answer
CISPLATIN, Armisarte 25 mg/ml concentrate for solution for infusion, CARBOPLATIN, PEMETREXED, TAGRISSO 80 mg film-coated tablets, PLACEBO, TAGRISSO 40 mg film-coated tablets for Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active